Language

Hu, Chun-Mei 胡春美

HuCM 6x7助研究員

CMHU1220gateEmail
02-2789-8777

 

EDUCATION AND POSITIONS HELD:

  • Ph.D., Institute of Biochemistry and Molecular Biology, National Taiwan University, College of Medicine, 2010
  • Postdoctoral Fellow, Institute of Biochemistry and Molecular Biology, National Yang-Ming University, 2010-2012
  • Postdoctoral Fellow, Department of Biological Chemistry, School of Medicine, University of California, Irvine, USA, 2012-2013
  • Postdoctoral Fellow, Genomics Research Center, Academia Sinica, 2013-2014
  • Regular Postdoctoral Fellow, Academia Sinica, 2014
  • Assisant Research Specialist, Genomics Research Center, Academia Sinica, 2014-2019
  • Assisant Professor, Genomics Research Center, Academia Sinica, 2019-present

HONORS:

  • Award for Excellent Ph.D. Thesis from the Chien-Tien Hsu Cancer Research Foundation at the 7th Symposium on Recent Advances in Cellular and Molecular Biology, 1999
  • Excellence Award The first session of the Merck Award for young biotech, 2008
  • Excellence Award National Taiwan University Graduate Award for outstanding work, 2008

EXPERTISE:

  • Nucleotide metabolism and genomic instability studies
  • Tumorigenic activity assay (including the determination of growth rate, mutation rate, soft-agar colony formation and tumorigenecity in nude/scid mice).
  • Polyclonal antibody generation
  • Develop method for high-throughput drug screening
  • Identify small molecules for targeted therapy
  • Uncover drug action mechanism

我的研究工作主要是從核酸代謝的角度去探討癌症的生成，進一步去建立高速篩選小分子藥物方法，辨別並分析藥物的作用效力與機制，以達到治療和預防癌症的目的。

PATENTS

  • Chang ZF, Fang JM, Hu CM, Yeh MT. Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells. US20130252953 A1, CN103476411A, WO2012072019A1. 2013
  • Lee WH, Zhu J, Qiu XL, Hu CM. Small Molecule Modifiers of The Hec1-Nek2 Interaction In G2/M. UC2013-847-1

SELECTED PUBLICATIONS:

  • Hsu YS, Wu PJ, Jeng YM, Hu CM*, Lee WH*., 2022, “Differential Effects of Glucose and N-acetylglucosamine on Genome instability.”, Am J Cancer Res, 12(4), 1556-1567. (SCIE)
  • Chen YI, Chang CC, Hsu MF, Jeng YM, Tien YW, Chang MC, Chang YT, Hu CM, Lee WH, 2022, “Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation.”, Nature communications, 13, 2945. (SCIE)
  • 1.Wu HH, Tsai LH, Huang CK, Hsu PH, Chen MY, Chen YI, Hu CM, Shen CN, Lee CC, Chang MC, Chang YT, Tien YW, Jeng YM, Lee EYP, Lee WH, 2021, “Characterization of Initial Key Steps of IL-17 Receptor B Oncogenic Signaling for Targeted Therapy of Pancreatic Cancer”, Science Translational Medicine, 13(583), eabc2823. (SCIE)
  • Hu CM*, Tien SC, Hsieh PK, Jeng YM, Chang MC, Chang YT, Chen YJ, Chen YJ, Lee EY and Lee WH, 2019, “High glucose triggers nucleotide imbalance through O-GlcNAcylation of key enzymes and induces KRAS mutation in pancreatic cells”, CELL METABOLISM, 29 (6),1334-1349.e10. (SCIE)
  • Chen YL, Hu CM, Hsu JT, Chang CC, Huang TY, Chiang PH, Chen WY, Chang YT, Chang MC, Tien YW, Lee EY, Jeng YM and Lee WH, 2018, “Cellular 5-hydroxylmethylcytosine content determines tumorigenic potential and prognosis of pancreatic ductal adenocarcinoma”, American journal of cancer research., 8(12),2548-2563.
  • Huang SC, Wei PC, Hwang-Verslues WW, Kuo WH, Jeng YM, Hu CM, Shew JY, Huang CS, Chang KJ, Lee EY and Lee WH, 2017, “TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB.”, EMBO molecular medicine, 9(12),1660-1680. (SCIE)
  • Huang CK, Chang PH, Kuo WH, Chen CL, Jeng YM, Chang KJ, Shew JY, Hu CM and Lee WH., 2017, “Adipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate.”, nature communications, 8,14706. (SCIE)
  • Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, Kim Y, Lopez R, Chamberlin AR, Lee EH, Lee WH., 2015, “Novel small molecules disrupting Hec1/Nek2 interaction ablates tumor progression by triggering Nek2 degradation through a death-trap mechanism.”, ONCOGENE, 1220-1230. (SCIE)
  • Ngo B, Hu CM, Guo XE, Ngo B, Wei R, Zhu J and Lee WH., 2013, “Complementary interhelical interactions between three buried Glu-Lys pairs within three heptad repeats are essential for Hec1-Nuf2 heterodimerization and mitotic progression.”, JOURNAL OF BIOLOGICAL CHEMISTRY, 288(48), 34403-34413. (SCIE)
  • Zhu J, Zhou L, Wu G, Konig H, Lin X, Li G, Qiu XL, Chen CF, Hu CM, Goldblatt E, Bhatia R, Chamberlin AR, Chen PL, Lee WH. , 2013, “A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.”, EMBO Molecular Medicine, 5(3), 353-365. (SCIE)
  • Hu CM, Yeh MT, Tsao N, Chen CW, Gao QZ, Chang CY, Lee MH, Fang JM, Sheu SY, Lin CJ, Tseng MC, Chen YJ, Chang ZF, 2012, “Tumor cells require thymidylate kinase to prevent dUTP incorporation during DNA repair.”, CANCER CELL, 22(1), 36-50. (SCIE)
  • Hu CM, Chang ZF , 2010, “A bioluminescent method for measuring thymidylate kinase activity suitable for high-throughput screening of inhibitor.”, ANALYTICAL CHEMISTRY, 398(2), 269-271. (SCIE)
  • Hu CM, Chang ZF., 2008, “Synthetic lethality by lentiviral short hairpin RNA silencing of thymidylate kinase and doxorubicin in colon cancer cells regardless of the p53 status.”, CANCER RESEARCH, 68(8), 2831-2840. (SCIE)
  • Hu CM, Chang ZF, 2007, “Mitotic control of dTTP pool: a necessity or coincidence? ”, JOURNAL OF BIOMEDICAL SCIENCE, 14(4), 491-497. (SCIE)
  • Ke PY, Hu CM, Chang YC, Chang ZF. , 2007, “Hiding human thymidine kinase 1 from APC/C- mediated destruction by thymidine binding.”, FASEB JOURNAL, 21(4), 1276-1284. (SCIE)
  • Ke PY, Kuo YY, Hu CM, Chang ZF., 2005, “Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. ”, GENES & DEVELOPMENT, 19(16), 1920-1933. (SCIE)